Scholarlink

<p>Diabetes mellitus is a persistent metabolic disease which impacts numerous individuals across the world because improper glycemic control triggers serious health problems. The current diabetes treatments like insulin therapy alongside oral antidiabetic drugs face limitations due to poor drug absorption together with multiple dosage needs and universal side effects so drug delivery approaches require improvement. The development of PLGA-based drug delivery systems represents a promising nanotechnology approach to overcome diabetes mellitus treatment obstacles. The review analyzes modern applications of PLGA-based nanoparticles in diabetes management by discussing their functions for insulin delivery control and oral therapies and pancreatic tissue construction. The three characteristics of PLGA support both sustained drug delivery and targeted therapy through biocompatibility and degradability while allowing various therapeutic agents to fit inside its structure to minimize administration while improving therapy effects. The combination of three novel approaches involving microneedle patches sensitive to glucose, insulin treatment with antioxidants, and biodegradable matrices for pancreatic repair and wound healing displays significant superiority for enhanced patient results. Experimental research proves that PLGA-encapsulated formulations succeed in improving both the therapeutic ratio of antidiabetic drugs like gliclazide and pioglitazone while simultaneously enhancing bioavailability and diabetic model glycemic management. The nanotechnology-based method for oral insulin delivery enables patient-adherent insulin administration through a non-invasive alternative to traditional injections which resembles natural insulin secretion. By uniting nanotechnology with personalized medicine, the field of diabetes treatment receives several novel pathways to drug delivery resulting in superior therapeutic results. The PLGA-based nanomedicine approach addresses the weaknesses of conventional diabetes treatments to establish more effective therapy that decreases complications and enhances patient treatment results. Future investigations will concentrate on maximizing delivery rates as well as integrating gene medicines with optimally refined development procedures to enhance diabetes care and worldwide healthcare solutions.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Nanotechnology in Diabetes Management: Advancements in PLGA-Based Drug Delivery

  • 期刊论文

  • 发表日期：

    2025年3月19日

查看全文
  • Saranya Balasubramaniyam,
  • Thirumalaikumaran Rathinam,
  • Mohanakrishnan Srinivasan,
  • Sowmiya Jayarani,
  • Karthikeyan Elumalai

摘要

Diabetes mellitus is a persistent metabolic disease which impacts numerous individuals across the world because improper glycemic control triggers serious health problems. The current diabetes treatments like insulin therapy alongside oral antidiabetic drugs face limitations due to poor drug absorption together with multiple dosage needs and universal side effects so drug delivery approaches require improvement. The development of PLGA-based drug delivery systems represents a promising nanotechnology approach to overcome diabetes mellitus treatment obstacles. The review analyzes modern applications of PLGA-based nanoparticles in diabetes management by discussing their functions for insulin delivery control and oral therapies and pancreatic tissue construction. The three characteristics of PLGA support both sustained drug delivery and targeted therapy through biocompatibility and degradability while allowing various therapeutic agents to fit inside its structure to minimize administration while improving therapy effects. The combination of three novel approaches involving microneedle patches sensitive to glucose, insulin treatment with antioxidants, and biodegradable matrices for pancreatic repair and wound healing displays significant superiority for enhanced patient results. Experimental research proves that PLGA-encapsulated formulations succeed in improving both the therapeutic ratio of antidiabetic drugs like gliclazide and pioglitazone while simultaneously enhancing bioavailability and diabetic model glycemic management. The nanotechnology-based method for oral insulin delivery enables patient-adherent insulin administration through a non-invasive alternative to traditional injections which resembles natural insulin secretion. By uniting nanotechnology with personalized medicine, the field of diabetes treatment receives several novel pathways to drug delivery resulting in superior therapeutic results. The PLGA-based nanomedicine approach addresses the weaknesses of conventional diabetes treatments to establish more effective therapy that decreases complications and enhances patient treatment results. Future investigations will concentrate on maximizing delivery rates as well as integrating gene medicines with optimally refined development procedures to enhance diabetes care and worldwide healthcare solutions.